Chris Pagel

Chris Pagel serves as the Market Development Manager at Omeros Corporation since October 2020, focusing on the commercial lead for innovative complement inhibitor therapies in the rare disease sector. Prior experience includes roles as Key Account Director at Coherus BioSciences, managing C-Suite relationships and contract negotiations for Udenyca, and Regional Sales Director at Spectrum Pharmaceuticals, where recognition included the Chairman's Circle award. Chris has also held various positions at Amgen and Merck, demonstrating a strong track record in oncology and account management. Chris holds an MBA from Washington University in St. Louis and a BSBA from the University of Missouri-Columbia.